我的前三 🥉#Melanoma #ESMO26 HBI-8000 联合 nivolumab 治疗晚期黑色素瘤 - III 期对比单用 nivolumab。
▪️ mPFS：11.7 对 7.4 个月 | HR 0.73
💥 ORR：41.4% 对 32.3%（p=0.0569）
🔴 G3/4 TRAEs：54.8% 对 17.9%
⚠️ HBI-8000 相关治疗致死 4 例
☝🏼获益在低肿瘤负荷/正常 LDH 疾病中似乎最强！
PFS 阳性，是的。新标准？OS？
@OncoAlert
@OncoReporte @myESMO @_SEOM @GrupoMelanoma
586 浏览 · 6 赞 · 3 转发 · 0 回复
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.orgResults from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)
https://esmocongress.esmo.orgFinal pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.orgPrimary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：Mario Balsa · x.com